{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:57:13Z","timestamp":1762513033990,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009509","name":"Directorate General of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009509","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.heliyon.2021.e08126","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T21:41:50Z","timestamp":1633383710000},"page":"e08126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The correlation between the level of 3-hydroxypropyl mercapturic acid, CYP2B6 polymorphisms, and hematuria occurrences after cyclophosphamide administration and its bioanalytical methods: A systematic review"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7217-7900","authenticated-orcid":false,"given":"Yahdiana","family":"Harahap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhan","family":"Nurahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denni Joko","family":"Purwanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arry","family":"Yanuar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2021.e08126_bib1","first-page":"209","article-title":"Global cancer STATISTICS 2020: GLOBOCAN estimates of incidence and MORTALITY worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"year":"2021","series-title":"360 Indonesia Fact Sheets","author":"World Health Organization","key":"10.1016\/j.heliyon.2021.e08126_bib2"},{"key":"10.1016\/j.heliyon.2021.e08126_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","volume":"55","author":"Veal","year":"2016","journal-title":"Eur. J. Cancer"},{"year":"2013","series-title":"Prescribing Information for Cyclophosphamide","author":"Food and Drug Administration","key":"10.1016\/j.heliyon.2021.e08126_bib4"},{"year":"2021","series-title":"Cyclophosphamide","author":"Ogino","key":"10.1016\/j.heliyon.2021.e08126_bib5"},{"key":"10.1016\/j.heliyon.2021.e08126_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000496331","article-title":"Severe hemorrhagic cystitis caused by cyclophosphamide and capecitabine therapy in breast cancer patients: two case reports and literature review","volume":"12","author":"Tanaka","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.heliyon.2021.e08126_bib7","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2147\/COPD.S214961","article-title":"CYP2B6 genetic polymorphisms influence chronic obstructive pulmonary disease susceptibility in the Hainan population","volume":"14","author":"Ding","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e08126_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.200700412","article-title":"Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease","volume":"52","author":"Stevens","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"issue":"6","key":"10.1016\/j.heliyon.2021.e08126_bib9","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1248\/bpb.b15-01022","article-title":"Recent progress in analytical methods for determination of urinary 3-hydroxypropylmercapturic acid, a major metabolite of acrolein","volume":"39","author":"Higashi","year":"2016","journal-title":"Biol. Pharm. Bull."},{"year":"2020","series-title":"Synthetic Biology - New Interdisciplinary Science","author":"Kadri","key":"10.1016\/j.heliyon.2021.e08126_bib10"},{"issue":"4","key":"10.1016\/j.heliyon.2021.e08126_bib11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FTD.0000000000000737","article-title":"Quantification of 3-hydroxypropyl mercapturic acid in the urine of patients with breast cancer to monitor cyclophosphamide toxicity","volume":"42","author":"Harahap","year":"2020","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.heliyon.2021.e08126_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.14740\/jmc3321","article-title":"Hemorrhagic cystitis with low-dose cyclophosphamide therapy for breast cancer: a rare occurrence","volume":"10","author":"Kumar","year":"2019","journal-title":"J.\u00a0Med. Cases"},{"key":"10.1016\/j.heliyon.2021.e08126_bib13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.heliyon.2021.e08126_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"Quadas-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"year":"2019","series-title":"Robvis: an R Package and Web Application for Visualising Risk-Of-Bias Assessments","author":"McGuinness","key":"10.1016\/j.heliyon.2021.e08126_bib15"},{"year":"2017","series-title":"The Genetics of Cancer","key":"10.1016\/j.heliyon.2021.e08126_bib16"},{"year":"2019","series-title":"How Chemotherapy Drugs Work","key":"10.1016\/j.heliyon.2021.e08126_bib17"},{"year":"2011","series-title":"Goodman & Gilman's Pharmacological Basis of Therapeutics","key":"10.1016\/j.heliyon.2021.e08126_bib18"},{"key":"10.1016\/j.heliyon.2021.e08126_bib19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejmech.2018.04.001","article-title":"Therapeutic journery of nitrogen mustard as alkylating anticancer agents: historic to future perspectives","volume":"151","author":"Singh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2021.e08126_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.24171\/j.phrp.2018.9.4.08","article-title":"The prevalence of CYP2B6 gene polymorphisms in malaria-endemic population of timor in East Nusa Tenggara Indonesia","volume":"9","author":"Hananta","year":"2018","journal-title":"Osong Publ. Health Res. Perspect."},{"key":"10.1016\/j.heliyon.2021.e08126_bib21","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.18632\/oncotarget.24148","article-title":"Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients","volume":"9","author":"Tecza","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2021.e08126_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.104.068973","article-title":"Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles","volume":"311","author":"Lang","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.heliyon.2021.e08126_bib23","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10251","article-title":"Acrolein\u2014an \u03b1,\u00df-unsaturated aldehyde: a review of oral cavity exposure and oral pathology effects","volume":"7","author":"Aizenbud","year":"2016","journal-title":"Rambam Maimonides Med. J."},{"issue":"3","key":"10.1016\/j.heliyon.2021.e08126_bib24","first-page":"199","article-title":"Mechanisms of hemorrhagic cystitis","volume":"2","author":"Haldar","year":"2014","journal-title":"Am. J. Clin. Expe. Urology"},{"year":"2019","series-title":"Liquid Chromatography-Tandem Mass Spectrometry (LC-MS\/MS). DKI Jakarta: PT","author":"Harmita","key":"10.1016\/j.heliyon.2021.e08126_bib25"},{"key":"10.1016\/j.heliyon.2021.e08126_bib26","series-title":"Analyst","article-title":"Current developments in LC-MS for pharmaceutical analysis","author":"Beccaria","year":"2020"},{"issue":"8","key":"10.1016\/j.heliyon.2021.e08126_bib27","first-page":"356","article-title":"Ultra performance liquid chromatography (UPLC)","volume":"4","author":"Samatha","year":"2015","journal-title":"World J. Pharm. Pharmaceut. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2021.e08126_bib28","first-page":"387","article-title":"Ultra high performance liquid chromatography (UPLC): a new Trend in analysis","volume":"5","author":"Shaikh","year":"2016","journal-title":"World J. Pharmaceut. Res."},{"issue":"2079","key":"10.1016\/j.heliyon.2021.e08126_bib29","first-page":"20150382","article-title":"Quantitative mass spectrometry: an overview","volume":"374","author":"Urban","year":"2016","journal-title":"Phil. Transact. Ser A, Math. Phy. Eng. Sci."},{"year":"2007","series-title":"Principles of Instrumental Analysis","author":"Skoog","key":"10.1016\/j.heliyon.2021.e08126_bib30"},{"key":"10.1016\/j.heliyon.2021.e08126_bib31","first-page":"51","article-title":"Mass spectrometry: detectors review","volume":"3","author":"Medhe","year":"2018","journal-title":"Ann. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.heliyon.2021.e08126_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jchromb.2016.09.028","article-title":"Bioanalytical method development and validation: critical concepts and strategies","volume":"1043","author":"Moein","year":"2017","journal-title":"J.\u00a0Chromatogr. B"},{"year":"2018","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Food and Drug Administration","key":"10.1016\/j.heliyon.2021.e08126_bib33"},{"year":"2011","series-title":"Guideline on Bioanalytical Method Validation","key":"10.1016\/j.heliyon.2021.e08126_bib34"},{"issue":"1","key":"10.1016\/j.heliyon.2021.e08126_bib35","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1038\/s41598-017-03226-6","article-title":"A\u00a0comprehensive analysis and annotation of human normal urinary proteome","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"year":"2016","series-title":"New Trends in Sample Preparation for Bioanalysis","author":"Drouin","key":"10.1016\/j.heliyon.2021.e08126_bib36"},{"year":"2012","series-title":"LC-MS in Drug Bioanalysis","key":"10.1016\/j.heliyon.2021.e08126_bib37"},{"key":"10.1016\/j.heliyon.2021.e08126_bib38","series-title":"Proteomic Profiling and Analytical Chemistry","first-page":"51","article-title":"Protein extraction and precipitation","author":"Nov\u00e1k","year":"2016"},{"key":"10.1016\/j.heliyon.2021.e08126_bib39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fneur.2018.00420","article-title":"Systemic acrolein elevations in mice with experimental autoimmune Encephalomyelitis and patients with multiple sclerosis","volume":"9","author":"Tully","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heliyon.2021.e08126_bib40","series-title":"Quantification of 3-Hydroxypropyl Mercapturic Acid in the Urine of Patients with Breast Cancer to Monitor Cyclophosphamide Toxicity","first-page":"548","author":"Harahap","year":"2020"},{"issue":"7","key":"10.1016\/j.heliyon.2021.e08126_bib41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1021\/tx700075y","article-title":"Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid Chromatography\u2212Atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking","volume":"20","author":"Carmella","year":"2007","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.heliyon.2021.e08126_bib42","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/chromsci\/48.3.194","article-title":"Development and validation of a Direct LC-MS-MS method to determine the acrolein metabolite 3-HPMA in urine","volume":"48","author":"Yan","year":"2010","journal-title":"J.\u00a0Chromatogr. Sci."},{"key":"10.1016\/j.heliyon.2021.e08126_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fgene.2020.00085","article-title":"A\u00a0new single nucleotide polymorphism database for North American Atlantic salmon generated through whole genome resequencing","volume":"11","author":"Gao","year":"2020","journal-title":"Front. Genet."},{"year":"2019","series-title":"Biochemistry Free for All. Oregon: LibreTexts","author":"Ahern","key":"10.1016\/j.heliyon.2021.e08126_bib44"},{"issue":"5","key":"10.1016\/j.heliyon.2021.e08126_bib45","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/1556-4029.13837","article-title":"The extraction and recovery efficiency of pure DNA for different types of swabs","volume":"63","author":"Bruijns","year":"2018","journal-title":"J.\u00a0Forensic Sci."},{"key":"10.1016\/j.heliyon.2021.e08126_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.forsciint.2018.03.035","article-title":"Simple DNA extraction of urine samples: effects of storage temperature and storage time","volume":"287","author":"Ng","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.heliyon.2021.e08126_bib47","article-title":"DNA quantification by real-time PCR in different forensic samples","volume":"5","author":"Martins","year":"2015","journal-title":"Forensic Sci. Int.: Genetics Suppl. Ser."},{"issue":"1","key":"10.1016\/j.heliyon.2021.e08126_bib48","article-title":"A\u00a0rapid and efficient DNA extraction protocol from fresh and frozen human blood samples","volume":"32","author":"Guha","year":"2017","journal-title":"J.\u00a0Clin. Lab. Anal."},{"issue":"5","key":"10.1016\/j.heliyon.2021.e08126_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4155\/bio-2018-0202","article-title":"High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS\/MS","volume":"11","author":"Kaewkhao","year":"2019","journal-title":"Bioanalysis"},{"year":"2016","series-title":"QIAamp DNA Mini and Blood Mini Handbook","key":"10.1016\/j.heliyon.2021.e08126_bib50"},{"issue":"6","key":"10.1016\/j.heliyon.2021.e08126_bib51","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FPC.0b013e328045c4fb","article-title":"Genetic polymorphisms of CYP2B6 affect the pharmacokinetics\/pharmacodynamics of cyclophosphamide in Japanese cancer patients","volume":"17","author":"Nakajima","year":"2007","journal-title":"Pharmacogenetics Genom."},{"issue":"5","key":"10.1016\/j.heliyon.2021.e08126_bib52","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1111\/ajco.13048","article-title":"Cyclophosphamide-induced hemorrhagic cystitis in young patients with solid tumors: a single institution study","volume":"14","author":"Saito","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2021.e08126_bib53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.rbr.2016.04.009","article-title":"Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review","volume":"57","author":"Teles","year":"2017","journal-title":"Rev. Bras. Reumatol."},{"key":"10.1016\/j.heliyon.2021.e08126_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/ijdd.ijdd_31_19","article-title":"Managing a side effect: cyclophosphamide-induced hemorrhagic cystitis","volume":"5","author":"Doshi","year":"2019","journal-title":"Indian J. Drugs Dermatol."},{"issue":"2","key":"10.1016\/j.heliyon.2021.e08126_bib55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bcp.12800","article-title":"Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus","volume":"81","author":"Shu","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2021.e08126_bib56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug\u2013drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.heliyon.2021.e08126_bib57","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front. Genet."},{"key":"10.1016\/j.heliyon.2021.e08126_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.heliyon.2021.e08126_bib59","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.heliyon.2021.e08126_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.tpj.6500157","article-title":"Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation","volume":"3","author":"Xie","year":"2003","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.heliyon.2021.e08126_bib61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2005.08.008","article-title":"Pharmacogenetics of cyclophosphamide in patients with hematological malignancies","volume":"27","author":"Xie","year":"2006","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.heliyon.2021.e08126_bib62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00008571-200310000-00005","article-title":"Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844021022295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844021022295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:51:19Z","timestamp":1762512679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844021022295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2405844021022295"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2021.e08126","relation":{},"ISSN":["2405-8440"],"issn-type":[{"type":"print","value":"2405-8440"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The correlation between the level of 3-hydroxypropyl mercapturic acid, CYP2B6 polymorphisms, and hematuria occurrences after cyclophosphamide administration and its bioanalytical methods: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2021.e08126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e08126"}}